---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-261670"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2026-06-08T20:02:15+00:00"
generated_at: "2026-06-08T20:03:57.503664+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# CG Oncology stockholders elect two Class II directors, ratify auditor at 2026 annual meeting

## Summary
- Christina Rossi elected with 67,531,501 shares for (99.87% of votes cast); Victor Tong Jr. elected with 62,401,874 shares for.
- Ernst & Young LLP ratified as independent auditor for FY2026 with 83,711,522 shares for (99.99% of votes cast).
- Say-on-pay approved on advisory basis with 65,894,959 shares for (97.6% of votes cast).
- Stockholders selected 1-year frequency for future advisory votes on executive compensation, with 66,962,791 shares for (99.2% of votes cast).
- Company will hold say-on-pay votes annually until next required frequency vote.

## SEC filing metadata
- accession: 0001193125-26-261670
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2026-06-08T20:02:15+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312526261670/0001193125-26-261670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312526261670/d54487d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-261670
- JSON: https://secwatch.observer/filing/0001193125-26-261670.json
- Plain text: https://secwatch.observer/filing/0001193125-26-261670.txt

## Key facts
- Shareholder Votes
  CG Oncology, Inc. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 1: Election of Directors The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Shares Voted For Shares Voted Withhold Broker Non-Votes Name of Directors Elected Christina Rossi 67,531,501 89,825 16,216,685 Victor Tong, Jr. 62,401,874 5,219,452 16,216,685
  evidence_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526261670/0001193125-26-261670-index.htm
- Shareholder Votes
  CG Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-04 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 3: Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results are as follows: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 65,894,959 1,603,011 123,356 16,216,685
  evidence_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526261670/0001193125-26-261670-index.htm
- Shareholder Votes
  CG Oncology, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Shares Voted For Shares Voted Against Abstentions 83,711,522 4,103 122,386
  evidence_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526261670/0001193125-26-261670-index.htm
- Shareholder Votes
  CG Oncology, Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-04 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 4: Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation The Company’s stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 66,962,791 4,269 537,270 116,996 16,216,685
  evidence_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526261670/0001193125-26-261670-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.